Stereotactic body radiotherapy plus lenvatinib and sintilimab with and without transarterial embolization for advanced hepatocellular carcinoma with portal vein tumor thrombus: a dual-center, propensity score-matched retrospective analysis.

Front Immunol · 2026 · PMC12996245 · PMID 41859127

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Our results indicated that adding TAE significantly prolonged the mPFS (11.0 vs 6.0 months, p=0.044) and showed a trend toward improved OS and LC.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.